Opportunities For Medtech In Mental Health

With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. In Vivo explores transcranial magnetic stimulation systems that are being used to treat severe anxiety and depression, among other indications. As well as the skyrocketing use of telehealth, apps and light therapy for mental health indications.  

Touch the future,Interface technology, the future of user experience.
Exploring opportunities in behavioral health and digital health

As people everywhere continue to face uncertainties and challenges during the COVID-19 pandemic, rates of depression, anxiety and feelings of hopelessness are also on the rise. According to a poll by the Kaiser Health Foundation, 45% of adults in the US reported their mental health had been negatively impacted due to worry and stress over the virus. Feelings of anxiety and depression are increasingly common, and thoughts of obsessive-compulsive disorder have also been heightened by fear of the virus.

This could add further strain to the provision of mental health services and lead to greater demand for alternative, device-based...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

test carousel

 
• By 

test carousel-In-Vivo

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By 

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By 

XXXXtesting